Ribone 35

/ Unipharm

One tablet weekly.
See prescribing information for full details.

Treatment of postmenopausal osteoporosis, to reduce the risk of vertebral fractures. Treatment of established postmenopausal osteoporosis, to reduce the risk of hip fractures. Prevention of osteoporosis in postmenopausal women with increased risk of osteoporosis. Treatment of osteoporosis in men at high risk of fracture.

Known hypersensitivity. Hypocalcemia, pregnancy and lactation, severe renal impairment.

Efficacy in the treatment of postmenopausal osteoporosis is related to the presence of low bone mineral density and/or prevalent fracture. Evidence to support efficacy in very elderly women (>80 years) is limited). History of esophageal disorders which delay esophageal transit or emptying. Patients who are unable to stay in the upright position for at least 30 minutes after taking the tablet. Hypocalcemia should be treated before starting therapy. Other disturbances of bone and mineral metabolism (e.g. parathyroid dysfunction, hypovitaminosis D) should be treated at the same time as starting therapy.
See prescribing information for full details.

Mild to moderate in severity and usually do not require cessation of therapy. Common reactions: Pain, dyspepsia, nausea, constipation, diarrhea, GI disorder, headache.
See prescribing information for full details.

medications containing polyvalent cations (e.g. calcium, magnesium, iron and aluminum).